Home/Filings/4/0001104659-23-073872
4//SEC Filing

Dudley Robert Michael 4

Accession 0001104659-23-073872

CIK 0001829635other

Filed

Jun 21, 8:00 PM ET

Accepted

Jun 22, 6:23 PM ET

Size

7.0 KB

Accession

0001104659-23-073872

Insider Transaction Report

Form 4
Period: 2023-06-20
Dudley Robert Michael
DirectorChief Executive Officer10% Owner
Transactions
  • Purchase

    Common Stock

    2023-06-20$2.55/sh+6,607$16,84770,262 total
  • Purchase

    Common Stock

    2023-06-21$2.65/sh+12,000$31,81882,262 total
Footnotes (2)
  • [F1]Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
  • [F2]Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

Issuer

Transcode Therapeutics, Inc.

CIK 0001829635

Entity typeother

Related Parties

1
  • filerCIK 0001854161

Filing Metadata

Form type
4
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 6:23 PM ET
Size
7.0 KB